Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy iTeos Therapeutics (ITOS) stock

Learn how to easily invest in iTeos Therapeutics stock.

iTeos Therapeutics, Inc
-$0.82 (-3.26%)

iTeos Therapeutics, Inc is a biotechnology business based in the US. iTeos Therapeutics shares (ITOS) are listed on the NASDAQ and all prices are listed in US Dollars. iTeos Therapeutics employs 68 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in iTeos Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ITOS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

iTeos Therapeutics stock price (NASDAQ: ITOS)

Use our graph to track the performance of ITOS stocks over time.

iTeos Therapeutics shares at a glance

Information last updated 2021-07-22.
Latest market close$20.54
52-week range$17.43 - $47.61
50-day moving average $23.78
200-day moving average $29.39
Wall St. target price$48.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.88

Buy iTeos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy iTeos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

iTeos Therapeutics price performance over time

Historical closes compared with the close of $20.54 from 2021-05-28

1 week (2021-07-15) N/A
1 month (2021-06-25) -19.32%
3 months (2021-04-26) -15.26%
6 months (2021-01-22) N/A
1 year (2020-07-22) N/A
2 years (2019-07-22) N/A
3 years (2018-07-22) N/A
5 years (2016-07-22) N/A

iTeos Therapeutics financials

Gross profit TTM $0
Return on assets TTM -14.27%
Return on equity TTM -20.49%
Profit margin 0%
Book value $8.91
Market capitalisation $882.5 million

TTM: trailing 12 months

Shorting iTeos Therapeutics shares

There are currently 841,849 iTeos Therapeutics shares held short by investors – that's known as iTeos Therapeutics's "short interest". This figure is 49.9% down from 1.7 million last month.

There are a few different ways that this level of interest in shorting iTeos Therapeutics shares can be evaluated.

iTeos Therapeutics's "short interest ratio" (SIR)

iTeos Therapeutics's "short interest ratio" (SIR) is the quantity of iTeos Therapeutics shares currently shorted divided by the average quantity of iTeos Therapeutics shares traded daily (recently around 886156.84210526). iTeos Therapeutics's SIR currently stands at 0.95. In other words for every 100,000 iTeos Therapeutics shares traded daily on the market, roughly 950 shares are currently held short.

However iTeos Therapeutics's short interest can also be evaluated against the total number of iTeos Therapeutics shares, or, against the total number of tradable iTeos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iTeos Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 iTeos Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0485% of the tradable shares (for every 100,000 tradable iTeos Therapeutics shares, roughly 49 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iTeos Therapeutics.

Find out more about how you can short iTeos Therapeutics stock.

iTeos Therapeutics share dividends

We're not expecting iTeos Therapeutics to pay a dividend over the next 12 months.

iTeos Therapeutics overview

Iteos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. .

Stocks similar to iTeos Therapeutics

Frequently asked questions

What percentage of iTeos Therapeutics is owned by insiders or institutions?
Currently 0.713% of iTeos Therapeutics shares are held by insiders and 87.931% by institutions.
How many people work for iTeos Therapeutics?
Latest data suggests 68 work at iTeos Therapeutics.
When does the fiscal year end for iTeos Therapeutics?
iTeos Therapeutics's fiscal year ends in December.
Where is iTeos Therapeutics based?
iTeos Therapeutics's address is: 139 Main Street, Cambridge, MA, United States, 02142
What is iTeos Therapeutics's ISIN number?
iTeos Therapeutics's international securities identification number is: US46565G1040

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site